199 related articles for article (PubMed ID: 23022519)
1. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
Rossi A; Pasquale R; Esposito C; Normanno N
Cancer Treat Rev; 2013 Aug; 39(5):489-97. PubMed ID: 23022519
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
3. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
[TBL] [Abstract][Full Text] [Related]
4. Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer.
Pennell NA
Clin Lung Cancer; 2011 Nov; 12(6):350-9. PubMed ID: 21723791
[TBL] [Abstract][Full Text] [Related]
5. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Barni S
Clin Lung Cancer; 2012 Mar; 13(2):107-14. PubMed ID: 22056888
[TBL] [Abstract][Full Text] [Related]
7. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
Patel JD; Pasche B; Argiris A
Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib for non-small-cell lung cancer treatment.
D'Incecco A; Cappuzzo F
Expert Opin Drug Saf; 2011 Nov; 10(6):987-96. PubMed ID: 21905963
[TBL] [Abstract][Full Text] [Related]
9. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.
Peters S; Zimmermann S; Adjei AA
Cancer Treat Rev; 2014 Sep; 40(8):917-26. PubMed ID: 25027951
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.
Zhang WQ; Li T; Li H
Med Sci Monit; 2014 Dec; 20():2666-76. PubMed ID: 25503781
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R
Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
18. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
19. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer.
Yoshida T; Zhang G; Haura EB
Biochem Pharmacol; 2010 Sep; 80(5):613-23. PubMed ID: 20519133
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib in the first-line treatment of non-small-cell lung cancer.
D'Arcangelo M; Cappuzzo F
Expert Rev Anticancer Ther; 2013 May; 13(5):523-33. PubMed ID: 23617344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
